Inhibikase Therapeutics, Inc. Email Format

Pharmaceutical ManufacturingDelaware, United States11-50 Employees

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies to modify the progression of cardiopulmonary diseases, with a primary program targeting pulmonary arterial hypertension (PAH). Its lead candidate, IKT-001, is a prodrug of imatinib designed for PAH, an orphan indication, building on imatinib’s long-standing clinical use and safety profile. The company has conducted non-human primate safety assessments and a bioequivalence study in healthy volunteers to establish dosing relative to imatinib, and has advanced a Phase 3 trial (IMPROVE-PAH) with initial site activation and pre-screening activities. Inhibikase is headquartered in Wilmington, Delaware, with additional offices in Boston, Massachusetts, and maintains a focused team within the pharmaceutical manufacturing and development space.

Get verified Inhibikase Therapeutics, Inc. emails free

Company overview Employee directory